hypertrophy, was referred to our hospital because of a polypoid gastric lesion first detected at another hospital after a complaint of epigastric discomfort. On admission, there was no enlargement of any superficial lymph node. Peripheral blood showed moderate anemia (RBC, 343 ϫ 10 4 /mm 3 ; hemoglobin [Hb], 8.9 g/dl; hematocrit [Ht], 27.3%), and serum showed hypoalbuminemia (albumin, 3.4 g/dl), minimally high C-reactive protein (CRP; 1.4 mg/dl; normal range, Ͻ0.6 mg/dl), normal levels of tumor markers (alpha-fetoprotein [AFP], 1.8 ng/ml, carcinoembryonic antigen [CEA], 1.2 ng/ml, and carbohydrate antigen [CA]19-9, Ͻ10 U/ ml) and various levels of gastrointestinal hormonesgastrin, 756 pg/ml; (normal range, 42-200 pg/ml); somatostatin, 23.0 pg/ml (normal range, 1-12 pg/ml); serotonin, 12.2 µg/dl (normal range, 10-30 µg/dl); glucagon, 43 pg/ml (normal range, 70-160 pg/ml); vasoactive intestinal peptide (VIP), Ͻ5 pg/ml (normal range, Ϲ100 pg/ ml); insulin, 6 µU/ml (normal range, 3-18 µU/ml).
; hemoglobin [Hb] , 8.9 g/dl; hematocrit [Ht], 27.3%), and serum showed hypoalbuminemia (albumin, 3.4 g/dl), minimally high C-reactive protein (CRP; 1.4 mg/dl; normal range, Ͻ0.6 mg/dl), normal levels of tumor markers (alpha-fetoprotein [AFP], 1.8 ng/ml, carcinoembryonic antigen [CEA], 1.2 ng/ml, and carbohydrate antigen [CA]19-9, Ͻ10 U/ ml) and various levels of gastrointestinal hormonesgastrin, 756 pg/ml; (normal range, 42-200 pg/ml); somatostatin, 23 .0 pg/ml (normal range, 1-12 pg/ml); serotonin, 12.2 µg/dl (normal range, 10-30 µg/dl); glucagon, 43 pg/ml (normal range, 70-160 pg/ml); vasoactive intestinal peptide (VIP), Ͻ5 pg/ml (normal range, Ϲ100 pg/ ml); insulin, 6 µU/ml (normal range, 3-18 µU/ml).
Gastric fluoroscopy ( Fig. 1) showed a large polypoid lesion consisting of multiple irregularly shaped nodules extending from the cardia to the body. Gastric endoscopy ( Fig. 2) showed a Type 1 (polypoid) lesion with an abrupt tumor margin and rough surface covered with whitish-yellowish exudate. The lesion was proven to be ECC by histological examination of a biopsy sample. Abdominal computed tomography (CT) (Fig. 3) showed an enhanced polypoid lesion and an enlarged lymph node adjacent to the posterior wall of the gastric body, but no liver metastasis.
Total gastrectomy (Fig. 4) and splenectomy was performed, without any complication. The surgical stage was IIIA (T3N1H0P0M0CY0) [48] . The histological diagnosis was gastric glandular-endocrine cell carcinoma, medullary-type, INF , ss, ly1, v2, n1 (#3), pm(Ϫ), dm(Ϫ), 10 ϫ 8.5 cm, type 1, Post, UM [48] . A histological adenocarcinoma component was recognized in the continuity of the ECC component (Fig. 5a-c) . Immunohistological staining of the ECC was strongly and
Introduction
Endocrine cell carcinoma (ECC) is rare in the gastrointestinal tract, accounting for about 1% of cancers in the esophagus, 0.2% in the colon, and 0.1%-0.4% in the stomach [1] [2] [3] . Gastric ECC shows various macroscopic types in the early stage [4] , but in patients with advanced disease, the expansive-ulcerative type is seen in more than half of the patients and the polypoid type is a minority [5, 6] . The biological behavior of gastric ECC is aggressive, as shown by frequent metastasis to liver and lymph nodes and the poor effectiveness of chemotherapy [4, [5] [6] [7] (Table 1) . Here, we report a patient with advanced gastric ECC of polypoid shape and large size, without any recurrence 1 year after gastrectomy.
Case report
A 67-year-old man, who had congenital hearing loss, diabetes mellitus, hypertension, and benign prostatic The patient did well in his postoperative course and was soon discharged, taking oral tegafur-uracil (UFT), 300 mg/day. One year after the operation, he was examined by abdominal CT scan, which showed no recurrence or liver metastasis.
Discussion
Early in the twentieth century, endocrine cell tumors were categorized as "carcinoid" because of their histological resemblance to carcinoma [50] . Later, carcinoids were histologically divided into four types (A to D) by Soga et al. [51] . In Japan, the category of gastric endo- diffusely positive for Grimelius, chromogranin, neuronspecific enolase (NSE) (Fig. 5d ), but negative for serotonin, gastrin, somatostatin, glucagon, insulin, pancreatic polypeptide, peptide YY, adrenocorticotropic hormone (ACTH), Fontana-Masson, MUC2, MUC5AC, and CD10. All of these immunostainings, except for Grimelius (focally positive) and CD10, were negative in the adenocarcinoma component. No hybrid cells, i.e., those with both adeno-and endocrine-cell characteristics, were recognized in the double-stained sections in which MUC2, MUC5AC, and CD10 were used for detecting adeno-characteristics and chromogranin and NSE were used for detecting endocrine characteristics. Immunostaining of p53 and Ki-67 [49] was strongly and diffusely positive in both the ECC and adenocarcinoma components. The yellowish-whitish crine cell carcinoma (ECC) was reported by Matsusaka et al. [1] . Endocrine cell tumors of the stomach have been classified as "classical-type carcinoid" and "endocrine cell carcinoma" (ECC) [2] , with different cell origin [4, 52] , biological behavior, and prognosis [3, 4] . Iwafuchi et al. [4] reported that most early gastric ECCs (76%) were located in the deep mucosa or submucosa and were adjacent to coexisting instramucosal differentiated adenocarcinomas. In our patient, an adenocarcinoma component was recognized in continuity with the ECC, which suggests ordinary histological carcinogenesis of an ECC or glandular-ECC. In the development of gastric endocrine cell tumor, possible factors are chronic hypergastrinemia due to type A gastritis [52] , pernicious anemia [53] , and longterm treatment with proton pump inhibitors (PPI) [54] . In our patient, although there was no history of pernicious anemia or PPI administration and no gastrin production in the tumor, the serum gastrin level was revealed to be high. Although the origin of this high level was unknown, this may have played an important role in the progression of the tumor, because most gastrointestinal hormones, except for somatostatin, promote the proliferation of both the gastrointestinal epithelium and of cancer [3] .
To date, 37 cases have been reported in the Japanese literature and 16 in the English-language literature, in terms of clinicopathology, therapies, and/or prognosis of gastric ECC (Table 1) . According to previous studies with clinicopathological analysis [5] [6] [7] 44] , the macroscopic appearance of gastric ECC varies in its early stage. However, when it is advanced, type 2 (tumorulcerative) is dominant and type 1 (fungating or polypoid), as in our patient, is less frequent [5, 6] . Matsui et al. [6] hypothesized that a crater-like ulceration develops, probably due to rapid proliferation, and that only a few tumors maintain a polypoid appearance in the advanced stage. Concerning treatment, because of the tumor's aggressive biological characteristics, intensive chemotherapy, with or without operation, is recommended for gastric ECC at any stage [44] . Previously, several chemotherapeutic menus have been employed for gastric ECCs, but their effectiveness has been shown in only a few patients [32, 46, 55] . Sakai et al. [32] showed complete remission in a 31-year-old man with gastric ECC with multiple bone metastasis (case 29 in Table 1 ), with seven cycles of chemotherapy consisting of cisplatin (CDDP), etoposide, cyclophosphamide, epirubicin, and vincristine, followed by high-dose chemotherapy and peripheral blood cell transplantation. O'Byrne et al. [46] reported that a 54-year-old man with gastric ECC with severe epigastralgia and weight loss (case 52 in Table 1 ) was treated with six cycles of CDE (cyclophosphamide, doxorubicin, etoposide) chemotherapy, resulting in 11 months of complete remission. In patients with neuroendocrine carcinoma or undifferentiated small cell carcinoma, including lung small cell carcinoma and extrapulmonary small cell carcinoma, PE (cisplatin and etoposide) and CDE chemotherapies have been thought to be effective [56, 57] . The tumor in our patient was resected curatively without distant metastsis, and this may explain the 1 year of survival in spite of the large tumor size and advanced stage. However, we thought it necessary to follow this patient carefully, because gastric ECCs show a high Ki-67 index, as in this patient [58] , and some of them relapse after long intervals, such as 747 days [55] .
